Skip to main content
Search
Search
South Africa | en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Brazil |
Português
Canada |
English
Canada |
Français
Central America |
Español
Colombia |
Español
Mexico |
Español
United States |
English
Australia |
English
Bangladesh |
English
Hong Kong S.A.R. |
繁體中文
India |
English
Indonesia |
English
Japan |
日本語
Korea |
한국어
Mainland China |
中文
Malaysia |
English
Pakistan |
English
Philippines |
English
Singapore |
English
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Bulgaria |
Български
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hungary |
Magyar
Ireland |
English
Italy |
Italiano
Latvia |
Latvian
Lithuania |
Lithuanian
Netherlands |
Nederlands
Norway |
Norsk
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Serbia |
Srpski
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Türkiye |
Türkçe
United Kingdom |
English
Global |
English
Novartis Foundation |
English
Egypt |
English
Israel |
עברית
Saudi Arabia |
العربية
South Africa |
English
South Africa
Choose Location
middle-east-africa
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Australia |
English
Austria |
Deutsch
Bangladesh |
English
Belgium |
Français
Belgium |
Nederlands
Brazil |
Português
Bulgaria |
Български
Canada |
English
Canada |
Français
Central America |
Español
Colombia |
Español
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Egypt |
English
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hong Kong S.A.R. |
繁體中文
Hungary |
Magyar
India |
English
Indonesia |
English
Ireland |
English
Israel |
עברית
Italy |
Italiano
Japan |
日本語
Korea |
한국어
Latvia |
Latvian
Lithuania |
Lithuanian
Mainland China |
中文
Malaysia |
English
Mexico |
Español
Netherlands |
Nederlands
Norway |
Norsk
Global |
English
Novartis Foundation |
English
Pakistan |
English
Philippines |
English
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Saudi Arabia |
العربية
Serbia |
Srpski
Singapore |
English
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
South Africa |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Türkiye |
Türkçe
United Kingdom |
English
United States |
English
Menu
About
Novartis in South Africa
Strategy
Diversity and Inclusion
People and Culture
PAIA Manuals
Contacts
About
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Diseases
Adverse Event Reporting
Patient Support and Engagement
Discovery & development
Patients and Caregivers
Healthcare Professionals
Healthcare professional country resource
Adverse Event Reporting
Novartis Clinical Trials
Grants & Sponsorships
Healthcare Professionals
ESG
Ethics, Risk and Compliance
Access
Environmental Sustainability
Global Health
Ethical Behavior
Corporate Responsibility
ESG
News
Recent News
News Archive
Stories
Contacts
News
Careers
Career Search
Meet the teams
Personal Growth
Early Talent
How We Work
Well-being
Diversity and Inclusion
Employee Benefits
Awards & Recognition
Careers
Coronavirus
Coronavirus
Home
Chronic Myeloid Leukemia (CML)
Understanding chronic myeloid leukaemia
Related Links
Diseases
AddToAny buttons
Share
Tweet
Share
Whatsapp
Linkedin
Email
Printable Links Block (Content)
Print
PDF
